Neoadjuvant PD-1 inhibitor plus chemotherapy in resectable esophageal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048917

Enrollment

Unknown

Registered

2021-07-19

Start date

2019-06-01

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

1:Neoadjuvant pembrolizumab and chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients over the age of 18 years old with histologically confirmed, treatment-na?ve ESCC of clinical stages II–IVA (according to the American Joint Committee on Cancer [AJCC] Prognostic Stage Groups, 8th ed., 2017 version) were eligible for inclusion.

Exclusion criteria

Exclusion criteria: The key exclusion criteria were:patients withactive autoimmune disease; patients withactive concurrent malignancy; and patients receiving ongoing systemic steroids(>10mg daily prednisone equivalents) or other immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
Safety and Efficacy;	—

Countries

Chian

Contacts

Public ContactXiaolong Yan

Department of Thoracic Surgery,Tangdu Hospital, Air Force Military Medical University

yanxiaolong@fmmu.edu.cn+86 15991269383

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026